ZIM
CNCE

Zacks Investment Management’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Zacks Investment Management’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-12,958
Closed -$164K – 597
2020
Q4 		$164K Sell
12,958
-473
-4% -$5.39K ﹤0.01% 506
2020
Q3 		$132K Hold
13,431
– – ﹤0.01% 488
2020
Q2 		$134K Buy
+13,431
New +$129K ﹤0.01% 484

Other funds holding CNCE

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Zacks Investment Management's CNCE Position: Q1 2021 in Review

Zacks Investment Management sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2021, closing a stake of 12,958 shares — an estimated $164K sold.

Zacks Investment Management first reported a position in CNCE in Q2 2020 and held it in 3 quarters. The position peaked at $164K in Q4 2020. 91 funds tracked by Wall St. Rank hold CNCE as of Q1 2021.

  • Zacks Investment Management reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2021 after selling out during the quarter.
  • Zacks Investment Management sold 12,958 Concert Pharmaceuticals, Inc. shares in Q1 2021, an estimated $164K.
  • Zacks Investment Management first reported a position in Concert Pharmaceuticals, Inc. in Q2 2020 and held it in 3 quarters.
  • Zacks Investment Management's Concert Pharmaceuticals, Inc. position peaked at $164K in Q4 2020.
  • 91 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2021.

Based on Zacks Investment Management's 13F filing for Q1 2021, filed 17 May 2021.